A Phase 2, Randomized, Double-blind,Active-controlled, Dose-ranging, Parallel-designStudy of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Study of New Drug (VX-548) in Patients with Painful Diabetic Peripheral Neuropathy
Sponsor: Vertex Pharmaceuticals
Enrolling: Male and Female Patients
Study Length: 5 Months
Clinic Visits: 10
IRB Number: AAAT9369
U.S. Govt. ID: NCT05660538
Contact: Jorge Cabrera, CRC: 212-305-6035 / jec2273@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety, tolerability, and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year.
This study is closed
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you a male and non-pregnant female patients between the ages of 18 and 80 years? Yes No
Have you been diagnosed with type 1 or type 2 diabetes? Yes No
Do you have a body mass index (BMI) of 18.0 to 40? Yes No
Do you have a history of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) within the last 2 years? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Jorge Cabrera, CRC
jec2273@cumc.columbia.edu
212-305-6035